Consequently, in a bench-to-bedside approach, the current translational study aims to identify targets that synergise with EGFR/ErbB inhibitors to overcome resistance issues and, thereby, increase and prolong treatment effects for patients with advanced chordoma. This evidence concerns the gene EGFR and chordoma.